StockNews.AI
TMCI
StockNews.AI
119 days

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

1. Class action lawsuit filed against Treace Medical for securities fraud allegations. 2. Company lowered 2024 revenue guidance from $220M-$225M to $201M-$211M. 3. Stock price plummeted 63% to $4.17 per share after the news. 4. Investors can join the lawsuit until June 10, 2025. 5. High-profile firm Pomerantz LLP is leading the class action against TMCI.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit and lowered revenue guidance strongly indicate ongoing operational issues, reminiscent of past struggles faced by companies like Theranos, which severely impacted stock performance due to legal troubles.

How important is it?

The lawsuit directly implicates Treace Medical's management, connecting to investor trust and stock valuation, paralleling situations that have led to steep declines in the past.

Why Short Term?

The immediate fallout from the lawsuit and revenue guidance is likely to affect stock prices swiftly, as seen when similar announcements led to rapid declines in stocks like Enron.

Related Companies

CLASS ACTION LAWSUIT FILED AGAINST TREACE MEDICAL CONCEPTS, INC.

NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Treace Medical Concepts, Inc ("Treace Medical" or the "Company") (NASDAQ: TMCI).

Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Treace Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until June 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Treace Medical securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

Click here for information about joining the class action

Company Press Release

After market hours on May 7, 2024, Treace Medical issued a press release reporting, among other things, that it lowered its full-year 2024 revenue guidance from between $220 million and $225 million to between $201 million and $211 million. During the associated earnings call the same day, the Company revealed competition from minimally invasive osteotomy and Lapiplasty "knockoffs" created headwinds for Lapiplasty growth.

On this news, the Company's stock price fell $6.95, or nearly 63%, to close at $4.17 per share on May 8, 2024, on unusually high trading volume.

About Pomerantz LLP

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Related News